APD 668
Alternative Names: APD668Latest Information Update: 16 Mar 2022
At a glance
- Originator Arena Pharmaceuticals
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 07 Sep 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 07 Jan 2008 Suspended - Phase-I for Type-2 diabetes mellitus in USA (PO)